Bausch Health Companies | VRX - Cost Of Sales


Bausch Health Companies reported $979M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Amgen USD 1.6B 187M Mar/2026
ANI Pharmaceuticals USD 114.5M 8.38M Mar/2026
Aurora Cannabis CAD 8.22M 80.38M Mar/2026
Bausch Health Companies USD 979M 55M Mar/2026
Biogen USD 797.5M 302M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Canopy Growth CAD 62.98M 9.91M Mar/2026
Corcept Therapeutics USD 2.88M 338K Mar/2026
Danaher USD 2.36B 512M Mar/2026
Drreddys Laboratories INR 32.13B 8.34B Mar/2026
Eli Lilly USD 3.58B 205M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novo Nordisk DKK 13.6B 1.55B Mar/2026
Pacira USD 50.74M 3.89M Mar/2026
Perrigo USD 643.7M 103.7M Mar/2026
Phibro Animal Health USD 240.42M 2.58M Dec/2025
Prestige Brands USD 140.76M 9.53M Mar/2026
Supernus Pharmaceuticals USD 49.04M 1.5M Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026
Zoetis USD 672M 71M Mar/2026